The PRISTINE registry of MedAlliance Inc.’s SELUTION SLR sirolimus-eluting balloon for below-the-knee artery disease has begun in Singapore, the Swiss company announced on 12 October.
PRISTINE is a 75-patient, single-center registry at the Singapore General Hospital that is evaluating SELUTION SLR in the treatment of infrainguinal occlusive lesions in patients with chronic limb-threatening ischemia.